COVID-19

Landmark women’s health study loses funding, a promising antibody-drug conjugate for breast cancer, a schizophrenia drug setback, and more news from this week.

Bacteria’s constant interaction with viruses has led them to evolve antiviral strategies.

Rhinoviruses, the main cause of the common cold, are unique among respiratory viruses.

Researchers designed a nanoparticle that inactivated a wide range of COVID-19 strains, potentially offering a broad-spectrum therapeutic approach.

Viral diseases like hepatitis don’t have many successful treatments available, so scientists are engineering antibodies to try and change that.

Pioneering approaches transform vaccine technologies and shape the future of disease prevention.

Pathogens invade mucosal surfaces like the nose, but typical vaccines don't mount an immune response there. Newly engineered mucosal vaccines, however, do.

Inhibiting an enzyme variant that contributes to severe COVID-19 in men holds promise for treating SARS-CoV-2 infections. 

Katalin Karikó and Drew Weissman received this year’s Physiology or Medicine award for their work on RNA biology and mRNA-based vaccines.

Robert Georgantas aims to expand the development of mRNA-based vaccines for a range of infectious diseases and cancers.